Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2013
08/15/2013US20130210786 Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders
08/15/2013US20130210785 Progesterone analogs and uses related thereto
08/15/2013US20130210784 Combinations and methods for treating non age-related hearing impairment in a subject
08/15/2013US20130210783 Neuroactive steroid compositions and methods of use therefor
08/15/2013US20130210782 Treating hyperglycemia with 25-hydroxyvitamin d3
08/15/2013US20130210780 Nutritional Composition for the Stimulation of Muscle Protein Synthesis
08/15/2013US20130210778 Formulation for the prevention of cardiovascular disease
08/15/2013US20130210776 Composition for the treatment of superficial lesions
08/15/2013US20130210775 Agent for inhibiting odor of pyrazine derivatives
08/15/2013US20130210774 Potent and selective inhibitors of hepatitis c virus
08/15/2013US20130210771 Methods and compositions for treating cancers
08/15/2013US20130210766 Compositions of small molecule therapeutics
08/15/2013US20130210765 Hyaluronic acid containing pharmaceutical or veterinary compositions
08/15/2013US20130210763 Synergism of gos and polyfructose
08/15/2013US20130210762 Solid pharmaceutical composition for neutralizing stomach acid
08/15/2013US20130210761 Methods and compositions for treating wounds utilizing chitosan compounds
08/15/2013US20130210760 Dermal filler compositions including antioxidants
08/15/2013US20130210759 Composition for Use in the Treatment of Acne
08/15/2013US20130210758 Formulation and method to induce a deep state of relaxation
08/15/2013US20130210755 Methods for inhibiting insect infestations
08/15/2013US20130210754 Method for producing an enriched extract from vitis vinifera l. leaves
08/15/2013US20130210753 Methods of treating muscular dystrophies
08/15/2013US20130210739 Bhlh proteins and their use as drugs
08/15/2013US20130210734 Method of preventing progression of hypertension-induced heart failure with pkc peptides
08/15/2013US20130210733 Methods of treating lung disease
08/15/2013US20130210726 Compositions and methods for treatment of peripheral vascular disease
08/15/2013US20130210723 Use of the Insulin-Like-Growth Factor 1 Splice Variant MGF for the Prevention of Myocardial Damage
08/15/2013US20130210721 Novel 3-hydroxyisothiazole 1-oxide derivatives
08/15/2013US20130210720 Treatment of heart failure
08/15/2013US20130210719 Treatment of heart failure
08/15/2013US20130210718 Biomarkers for Cardiodiabetes
08/15/2013US20130210717 Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1
08/15/2013US20130210701 Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof
08/15/2013US20130210700 Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof
08/15/2013US20130210158 Quaternary nitrogen heterocyclic compounds for detecting aqueous monosaccharides in physiological fluids
08/15/2013US20130210136 Methods For Treating Cardio Pulmonary Diseases With NO Group Compounds
08/15/2013US20130210116 Composition and methods for the diagnosis and treatment of tumor
08/15/2013US20130209586 Prevention And Treatment Of Cardiac Arrhythmias
08/15/2013US20130209583 Methods and compositions suitable for promoting healthy skin
08/15/2013US20130209580 Method for treating alzheimer's disease
08/15/2013US20130209579 Therapeutic combination for the treatment of cancer
08/15/2013US20130209578 Combinatory Cancer Treatment
08/15/2013US20130209577 Buffered Upper GI Absorption Promoter
08/15/2013US20130209567 Modified Release Dosage Forms of Skeletal Muscle Relaxants
08/15/2013US20130209566 Nanoparticle composition and methods to make and use the same
08/15/2013US20130209565 Posology and administration of glucocorticoid based compositions
08/15/2013US20130209563 Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
08/15/2013US20130209562 Methods and devices for providing prolonged drug therapy
08/15/2013US20130209561 Abuse-resistant opioid dosage form
08/15/2013US20130209560 Abuse-resistant formulations
08/15/2013US20130209559 Method for treating intestinal diseases presenting at least one inflammatory component
08/15/2013US20130209558 Oral Dosage Forms of Bendamustine and Therapeutic Use Thereof
08/15/2013US20130209556 Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
08/15/2013US20130209555 Formulations and Dosage Forms of Oxidized Phospholipids
08/15/2013US20130209553 Extended release pharmaceutical compositions of pramipexole
08/15/2013US20130209552 Aripiprazole compositions and methods for its transdermal delivery
08/15/2013US20130209550 Anti-Viral Azide Containing Compounds
08/15/2013US20130209549 Materials and methods for treating neurodegenerative diseases
08/15/2013US20130209546 Combinatorial methods and compositions for treatment of melanoma
08/15/2013US20130209545 Topical therapeutic formulations
08/15/2013US20130209543 Enhanced treatment regimens using mtor inhibitors
08/15/2013US20130209540 Multi-layer nicotine-containing pharmaceutical composition
08/15/2013US20130209531 Applications of partially and fully sulfated hyaluronan
08/15/2013US20130209525 Controlled release formulations of opioid and nonopioid analgesics
08/15/2013US20130209522 Drug Release from a Polymer-Controlled Local Antibiotic Delivery System Using a Degradable Bone Graft
08/15/2013US20130209521 Nanostructured aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them
08/15/2013US20130209519 Formulations of flibanserin
08/15/2013US20130209518 Combinations and modes of administration of therapeutic agents and combination therapy
08/15/2013US20130209517 Cancer therapy
08/15/2013US20130209516 Immunomodulatory compositions
08/15/2013US20130209505 Crystalline form of (2s,4r)-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-4-[(1h-[1,2,3]triazole-4-carbonyl)-amino]-pentanoic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester
08/15/2013US20130209496 Synergistic Effects Between Auristatin-Based Antibody Drug Conjugates And Inhibitors Of The PI3K-AKT mTOR Pathway
08/15/2013US20130209490 Diagnostic BioMarkers for Fibrotic Disorders
08/15/2013US20130209488 Methods and compositions for malic enzyme 2 (me2) as a target for cancer therapy
08/15/2013US20130209484 Selective ampd2 inhibitors and methods for using the same
08/15/2013US20130209483 Cannabidinoid derivatives
08/15/2013US20130209468 Use of MIF and MIF Pathway Agonists
08/15/2013US20130209461 Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
08/15/2013US20130209459 TREATMENT WITH ANTI-ErbB2 ANTIBODIES
08/15/2013US20130209452 Gene defects and mutant alk kinase in human solid tumors
08/15/2013US20130209446 Copy Number Variant-Dependent Genes As Diagnostic Tools, Predictive Biomarkers And Therapeutic Targets
08/15/2013US20130209444 Non-anticoagulant sulfated or sulfonated polysaccharides
08/15/2013US20130209442 Wound cleaning chemical composition and method for manufacturing
08/15/2013US20130209441 Process for inhibition of cerebral damage associated with ischemia by anthocyanins and anthocyanidins
08/15/2013US20130209440 Methods and compositions for the treatment of insulin-associated medical conditions
08/15/2013US20130209436 Lysosomal storage disease enzymes
08/15/2013US20130209433 Modulation of amino acid metabolism in the hypothalamus
08/15/2013US20130209432 Product and process for liquefaction of mucus or sputum
08/15/2013US20130209429 Modulation of Tissue Fatty Acid Composition of a Host by Human Gut Bacteria
08/15/2013US20130209408 Bacteriophage-containing therapeutic agents
08/15/2013US20130209403 Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection
08/15/2013US20130209401 Compositions and methods for inhibiting entry of a hepatic virus
08/15/2013US20130209400 Pyrazole derivatives as jak inhibitors
08/15/2013US20130209399 Anti-virus therapy for respiratory diseases
08/15/2013US20130209397 Heterocyclic antiviral compounds
08/15/2013US20130209388 Conditioning composition additive for providing immediate and long lasting benefits to keratin substrates
08/15/2013US20130209386 New uses
08/15/2013US20130209384 Treatment and composition for achieving skin anti-aging benefits by corneum protease activation
08/15/2013US20130209381 Topical application of ivermectin for the treatment of dermatological conditions/afflictions
08/15/2013US20130209380 Moisturizing composition with spf 30
1 ... 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 ... 7860